Lipaglyn 4mg Tablet

About

Lipaglyn 4mg Tablet, containing saroglitazar, is a novel therapeutic agent classified as a dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist. This unique mechanism of action allows it to target both lipid and glucose metabolism pathways, offering comprehensive benefits for patients with specific metabolic disorders. By activating PPAR-alpha, saroglitazar effectively reduces elevated triglyceride levels and improves high-density lipoprotein (HDL) cholesterol, addressing dyslipidemia. Concurrently, its PPAR-gamma agonism enhances insulin sensitivity in peripheral tissues, leading to improved glycemic control and reduced insulin resistance, which is crucial for managing type 2 diabetes.

Primarily indicated for diabetic dyslipidemia and non-alcoholic steatohepatitis (NASH) in certain regions, Lipaglyn provides a multifaceted approach to metabolic health. It helps to lower fasting plasma glucose, postprandial glucose, and HbA1c, while also improving various lipid parameters. Its dual action makes it a valuable option for patients who require both glycemic and lipid management, potentially mitigating the progression of cardiovascular complications and liver disease associated with these conditions. The once-daily oral administration further contributes to patient convenience and adherence.

Uses

• Management of diabetic dyslipidemia.
• Treatment of type 2 diabetes mellitus with dyslipidemia.
• Management of non-alcoholic steatohepatitis (NASH).
• Reduction of elevated triglyceride levels.

Directions For Use

Take orally, once daily, with or without food, as directed by your physician. Swallow the tablet whole with water.

Benefits

• Improves lipid profile by lowering triglycerides and LDL.
• Increases beneficial HDL cholesterol levels.
• Enhances insulin sensitivity and improves glycemic control.
• Potential benefits in managing non-alcoholic steatohepatitis (NASH).
• Offers a dual mechanism of action for comprehensive metabolic benefits.
• Convenient once-daily oral dosing.

Side Effects

• Peripheral edema (swelling)
• Weight gain
• Headache
• Nausea
• Diarrhea
• Upper respiratory tract infection
• Dizziness
• Fatigue
• Elevated liver enzymes
• Anemia
• Rash
• Hypoglycemia (rare, especially in monotherapy)

Safety Measures

• Alcohol - Excessive alcohol intake can worsen liver conditions and may interact with medication. Avoid or limit alcohol consumption and consult your doctor.
• Pregnancy - Not recommended during pregnancy due to insufficient data. Use effective contraception if you are a woman of childbearing potential.
• Breastfeeding - Not recommended during breastfeeding due to lack of data on excretion into breast milk. Consult your doctor.
• Liver - Contraindicated in active liver disease or significantly elevated liver enzymes. Regular monitoring of liver function tests is essential during treatment.
• Kidney - Use with caution in severe renal impairment. Dose adjustment may be needed based on kidney function.
• Lung - No specific contraindications or precautions related to lung conditions are typically associated with saroglitazar use.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.